Month: June 2026

Introduction and Objective: Multidisciplinary obesity and diabetes care requires coordination across providers and multiple data sources, often involving extensive time on documentation and chart review. We evaluated whether implementation of a real-time, AI-generated structured patient summary could improve clinician efficiency and satisfaction.Methods: In a large nationwide virtual obesity clinic, we conducted a pre-post evaluation of […]

Introduction and Objective: miRNAs are emerging as significant metabolic regulators and are altered at both the cellular and secreted levels in diseases, including type 2 diabetes (T2D). However, to what extent alterations in miRNA content and secretion are cell-intrinsic, and how they play a role in disease pathogenesis, remains unclear.Methods: In the present study, we […]

Introduction and Objective: Exocrine pancreas dysfunction is evident in presymptomatic type 1 diabetes (T1D), yet its natural history remains unclear. We evaluated whether longitudinal decline in fecal elastase (FE-1) tracks more closely with islet autoimmunity or progression to dysglycemia and assessed its predictive utility.Methods: In a nested case-control study within The Environmental Determinants of Diabetes […]

Introduction and Objective: Insulin resistance is a major risk factor in the development of type 2 diabetes (T2D) and metabolic syndrome. Although ~25% of people within the general non-diabetic population are insulin resistant, the primary underlying cause of insulin resistance remains elusive.Methods: In this study, we have used induced pluripotent stem cells (iPSC) derived from […]

Introduction and Objective: We are developing an ultra-stable insulin analog designed to address the intrinsic physical instability of current insulin formulations. Using advanced protein structural insights and protein engineering approaches originating from UT Southwestern, we focused on optimizing insulin analogs to reduce fibrillation and aggregation while improving resistance to thermal and mechanical stress across a […]

Introduction and Objective: T1D Exchange Quality Improvement Collaborative (T1DX-QI) administered a survey to evaluate characteristics of patient and clinic workforce and QI initiatives underway to support people with type 1 and type 2 diabetes (PwT1D and PwT2D).Methods: The T1DX-QI survey was administered August-October 2025 to collect 2024 data. Descriptive analyses summarized racial/ethnic diversity of clinical […]

Introduction and Objective: Fatty liver index (FLI) is a diagnostic tool in metabolic dysfunction-associated steatotic liver disease, an end-organ complication in overweight/obesity. This post hoc analysis assessed the impact of injectable semaglutide (sema) 2.4 mg versus placebo on FLI scores in STEP 1.Methods: People with information needed to calculate FLI scores (BMI, waist circumference, triglycerides […]

Introduction and Objective: Diabetic peripheral neuropathy remains a major therapeutic challenge, with over 50% of patients responding inadequately to existing non-opioid therapies (gabapentinoids, SNRIs, TCAs). Dorsal root ganglion (DRG) neurons serve as the primary sites for injury-induced plasticity underlying painful peripheral pathophysiologies. Voltage-gated sodium channels (VGSC), specifically Nav1.8, are highly expressed in DRGs and are […]

Introduction and Objective: In the SURPASS-4 clinical trial in patients with type 2 diabetes (T2D) at high cardiovascular risk, once-weekly treatment with the dual GLP-1/GIP receptor agonist, tirzepatide (TZP) resulted in substantial weight reduction, slower kidney function decline, and reduced albuminuria compared to insulin glargine. This post-hoc analysis evaluated the effect of TZP on 52-week […]

Introduction and Objective: Body mass index (BMI) alone may miss obesity risk; ICMR-INDIAB study supports metabolic phenotyping into four groups based on their metabolic and BMI status: metabolically healthy non-obese (MHNO), metabolically obese non-obese (MONO), metabolically obese obese (MOO), and metabolically healthy obese (MHO). We assessed phenotype distribution and association with liver fibrosis stage using […]